These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28418863)

  • 1. GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.
    Tsou YK; Liang KH; Lin WR; Chang HK; Tseng CK; Yeh CT
    Oncotarget; 2017 Apr; 8(17):29151-29160. PubMed ID: 28418863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers.
    Chen F; Luo H; Xing L; Liang N; Xie J; Zhang J
    Thorac Cancer; 2018 Jan; 9(1):59-65. PubMed ID: 29024498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
    Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF
    Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Chang CL; Tsai HC; Lin WC; Chang JH; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Radiother Oncol; 2017 Oct; 125(1):73-79. PubMed ID: 28923576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone.
    Zhang P; Xi M; Zhao L; Li QQ; He LR; Liu SL; Shen JX; Liu MZ
    Radiat Oncol; 2014 Nov; 9():256. PubMed ID: 25424871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
    Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
    BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
    Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide Study.
    Chao YK; Chen HS; Wang BY; Hsu PK; Liu CC; Wu SC
    Ann Thorac Surg; 2016 May; 101(5):1897-902. PubMed ID: 26912307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
    Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
    Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
    Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K; Beitler JJ; Shin DM; Willingham FF; El-Rayes B; Landry JC; Fernandez FG; Saba NF
    Cancer; 2017 Sep; 123(18):3476-3485. PubMed ID: 28464264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The association between polymorphism of transforming growth factor-β1 and radiochemotherapy response and survival in esophageal squamous cell carcinoma patients].
    Zhou YL; Zhang WC; Chen XB; Xiao ZF; Qiao Y; Yu DK; Lin DX; Tan W
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jul; 45(7):583-7. PubMed ID: 22041558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
    Xu Y; Zheng Y; Sun X; Yu X; Gu J; Wu W; Zhang G; Hu J; Sun W; Mao W
    Oncotarget; 2015 Nov; 6(35):38429-39. PubMed ID: 26392415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors of radiotherapy in patients with node-positive thoracic esophageal squamous cell carcinoma after radical surgery.
    Lu JC; Tao H; Chen ZZ; Qian PD
    Dis Esophagus; 2009; 22(6):490-5. PubMed ID: 19191849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
    Alakus H; Bollschweiler E; Hölscher AH; Warnecke-Eberz U; Frazer KA; Harismendy O; Lowy AM; Mönig SP; Eberz PM; Maus M; Drebber U; Siffert W; Metzger R
    Ann Surg Oncol; 2014 Dec; 21(13):4375-82. PubMed ID: 24986238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.
    Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
    Ordu AD; Nieder C; Geinitz H; Scherer V; Kup PG; Schuster T; Combs SE; Fakhrian K
    Anticancer Res; 2014 Dec; 34(12):7255-61. PubMed ID: 25503157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.